$6.57
-0.29 (-4.23%)
Open$6.58
Previous Close$6.86
Day High$6.67
Day Low$6.17
52W High$31.00
52W Low$4.51
Volume—
Avg Volume42.0K
Market Cap10.31M
P/E Ratio—
EPS$-0.08
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+102.0% upside
Current
$6.57
$6.57
Target
$13.27
$13.27
$11.80
$13.27 avg
$20.48
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 7.67M | 5.50M | 18.13M |
| Net Income | -4,873,440 | -3,142,577 | 507.1K |
| Profit Margin | -63.5% | -60.4% | 2.8% |
| EBITDA | -5,005,831 | -3,407,279 | 911.5K |
| Free Cash Flow | — | — | 739.6K |
| Rev Growth | +39.6% | +39.6% | +2.0% |
| Debt/Equity | — | — | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |